These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 15293980)

  • 21. [The role of peroxisome proliferator-activated receptor gamma in the pathogenesis of diabetes and atheromatosis].
    Gacka M; Adamiec R; Dobosz T; Szymaniec S; Bednarska-Chabowska D
    Przegl Lek; 2004; 61(12):1436-9. PubMed ID: 15850344
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 5-aryl thiazolidine-2,4-diones: discovery of PPAR dual alpha/gamma agonists as antidiabetic agents.
    Desai RC; Han W; Metzger EJ; Bergman JP; Gratale DF; MacNaul KL; Berger JP; Doebber TW; Leung K; Moller DE; Heck JV; Sahoo SP
    Bioorg Med Chem Lett; 2003 Aug; 13(16):2795-8. PubMed ID: 12873517
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Peroxisome proliferator-activated receptor gamma agonist improves arterial stiffness in patients with type 2 diabetes mellitus and coronary artery disease.
    Yu J; Jin N; Wang G; Zhang F; Mao J; Wang X
    Metabolism; 2007 Oct; 56(10):1396-401. PubMed ID: 17884451
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interaction between peroxisome proliferator-activated receptor gamma and its agonists: docking study of oximes having 5-benzyl-2,4-thiazolidinedione.
    Iwata Y; Miyamoto S; Takamura M; Yanagisawa H; Kasuya A
    J Mol Graph Model; 2001; 19(6):536-42, 598-600. PubMed ID: 11552681
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications.
    Touyz RM; Schiffrin EL
    Vascul Pharmacol; 2006 Jul; 45(1):19-28. PubMed ID: 16782410
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discovery of a novel series of peroxisome proliferator-activated receptor alpha/gamma dual agonists for the treatment of type 2 diabetes and dyslipidemia.
    Liu K; Xu L; Berger JP; Macnaul KL; Zhou G; Doebber TW; Forrest MJ; Moller DE; Jones AB
    J Med Chem; 2005 Apr; 48(7):2262-5. PubMed ID: 15801817
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Dipeptidylpeptidase IV inhibitors and dual action PPAR-agonists].
    Heinzl S
    Med Monatsschr Pharm; 2006 Mar; 29(3):93-6. PubMed ID: 16550882
    [No Abstract]   [Full Text] [Related]  

  • 28. Biology and toxicology of PPARgamma ligands.
    Tugwood JD; Montague CT
    Hum Exp Toxicol; 2002 Aug; 21(8):429-37. PubMed ID: 12412636
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PPAR-gamma agonists: therapeutic role in diabetes, inflammation and cancer.
    Murphy GJ; Holder JC
    Trends Pharmacol Sci; 2000 Dec; 21(12):469-74. PubMed ID: 11121836
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Selective PPAR agonists for the treatment of type 2 diabetes.
    Nehlin JO; Mogensen JP; Petterson I; Jeppesen L; Fleckner J; Wulff EM; Sauerberg P
    Ann N Y Acad Sci; 2006 May; 1067():448-53. PubMed ID: 16804025
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dual PPAR alpha/gamma agonists: promises and pitfalls in type 2 diabetes.
    Ahmed I; Furlong K; Flood J; Treat VP; Goldstein BJ
    Am J Ther; 2007; 14(1):49-62. PubMed ID: 17303976
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Obesity, peroxisome proliferator-activated receptor, and atherosclerosis in type 2 diabetes.
    Blaschke F; Takata Y; Caglayan E; Law RE; Hsueh WA
    Arterioscler Thromb Vasc Biol; 2006 Jan; 26(1):28-40. PubMed ID: 16239592
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Farnesoid X receptor: from structure to potential clinical applications.
    Pellicciari R; Costantino G; Fiorucci S
    J Med Chem; 2005 Aug; 48(17):5383-403. PubMed ID: 16107136
    [No Abstract]   [Full Text] [Related]  

  • 34. PPAR ligands: are they potential agents for cardiovascular disorders?
    Balakumar P; Rose M; Singh M
    Pharmacology; 2007; 80(1):1-10. PubMed ID: 17496434
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MK-767. Kyorin/Banyu/Merck.
    Calkin AC; Thomas MC; Cooper ME
    Curr Opin Investig Drugs; 2003 Apr; 4(4):444-8. PubMed ID: 12808885
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Design, synthesis, and activity evaluation of GK/PPARĪ³ dual-target-directed ligands as hypoglycemic agents.
    Lu J; Lei L; Huan Y; Li Y; Zhang L; Shen Z; Hu W; Feng Z
    ChemMedChem; 2014 May; 9(5):922-7. PubMed ID: 24737574
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discovery of a novel class of 1,3-dioxane-2-carboxylic acid derivatives as subtype-selective peroxisome proliferator-activated receptor alpha (PPARalpha) agonists.
    Aoki T; Asaki T; Hamamoto T; Sugiyama Y; Ohmachi S; Kuwabara K; Murakami K; Todo M
    Bioorg Med Chem Lett; 2008 Mar; 18(6):2128-32. PubMed ID: 18280733
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Type 2 diabetes, psoriasis and thiazolidinediones.
    Krentz AJ; Friedmann PS
    Int J Clin Pract; 2006 Mar; 60(3):362-3. PubMed ID: 16494655
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Drug evaluation: K-111, an insulin-sensitizing peroxisome proliferator-activated receptor alpha agonist.
    Drew BG; Calkin AC
    Curr Opin Investig Drugs; 2007 Apr; 8(4):324-30. PubMed ID: 17458183
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach.
    Bays H; Mandarino L; DeFronzo RA
    J Clin Endocrinol Metab; 2004 Feb; 89(2):463-78. PubMed ID: 14764748
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.